Lone-star pharma

A researcher at Lexicon Pharmaceuticals Credit: Courtesy of Lexicon Pharmaceuticals" />A researcher at Lexicon Pharmaceuticals Credit: Courtesy of Lexicon Pharmaceuticals Thirty miles north of Houston, texas - and a world away from the biopharmaceutical industry's hubs in California and New Jersey - sits The Woodlands, a sylvan community and home to the headquarters of Lexicon Pharmaceuticals. The compan

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Thirty miles north of Houston, texas - and a world away from the biopharmaceutical industry's hubs in California and New Jersey - sits The Woodlands, a sylvan community and home to the headquarters of Lexicon Pharmaceuticals.

The company was founded in 1995 as Lexicon Genetics, and until last year focused almost exclusively on creating knockout models by the thousands for drug target discovery. This past year, Lexicon shifted gears, moving into the commercial development of drugs. With the organizational change came a new name, Lexicon Pharmaceuticals, soon followed by layoffs of 120 people out of a workforce of about 700 people. Despite the change, Lexicon employees gave their company good marks, winning ninth place in this year's Best Places to Work in Industry overall list, up from 26th place the previous year.

"We all agree that we have a common goal," says Lexicon's associate director of oncology, Rick Finch. "We're ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies